Cargando…

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system

Background: In the emergent situation of COVID-19, off-label therapies and newly developed vaccines may bring the patients more adverse drug event (ADE) risks. Data mining based on spontaneous reporting systems (SRSs) is a promising and efficient way to detect potential ADEs to help health professio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Qiang, Duan, Shaojun, Liu, Yaxi, Yuan, Yinxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730807/ https://www.ncbi.nlm.nih.gov/pubmed/36506542 http://dx.doi.org/10.3389/fphar.2022.954359

Ejemplares similares

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
por: Wang, Wei, et al.
Publicado: (2023)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
por: Zhang, Lin, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
por: Jeong, Eugene, et al.
Publicado: (2022)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
por: Yang, Renjun, et al.
Publicado: (2022)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
por: Zhou, Shuang, et al.
Publicado: (2022)

Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system
por: Onda, Kenji, et al.
Publicado: (2023)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Tamura, Takao, et al.
Publicado: (2012)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2021)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Propensity score‐adjusted three‐component mixture model for drug‐drug interaction data mining in FDA Adverse Event Reporting System
por: Wang, Xueying, et al.
Publicado: (2019)

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
por: Huang, Jing, et al.
Publicado: (2023)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System
por: Wang, Liwei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gp0ubdcbf3q8n0mfl8fe100ip4